Dixon Hughes Goodman Wealth Advisors’s BridgeBio Pharma BBIO Stock Holding History

Dixon Hughes Goodman Wealth Advisors’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$5K	Buy	+500	New	+$5.13K	﹤0.01%	588

Other funds holding BBIO

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

AIG

American International Group New York $609M AUM 23.67% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Dixon Hughes Goodman Wealth Advisors's BBIO Position: Q1 2022 in Review

Dixon Hughes Goodman Wealth Advisors opened a new position in BridgeBio Pharma (BBIO) in Q1 2022: 500 shares worth $5K. The stake represents ﹤0.01% of the portfolio and ranks #588 among its holdings.

178 funds tracked by Wall St. Rank hold BBIO as of Q1 2022.

Dixon Hughes Goodman Wealth Advisors held 500 shares of BridgeBio Pharma worth $5K as of Q1 2022.
BridgeBio Pharma was a new Dixon Hughes Goodman Wealth Advisors position in Q1 2022.
BridgeBio Pharma made up ﹤0.01% of Dixon Hughes Goodman Wealth Advisors's portfolio in Q1 2022, its #588 holding.
178 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2022.

Based on Dixon Hughes Goodman Wealth Advisors's 13F filing for Q1 2022, filed 4 Apr 2022.